IPA response to Pfizer’s letter

IPA’s response to Pfizer letter of 23 May 2013 and Testimony before the
Subcommittee on Commerce, Manufacturing and Trade of the House Committee of
Energy and Commerce on 27 June 2013.

Acces the letter here

This entry was posted in Evergreening, Generics, IP Rights, IPR Enforcement, Novartis Case, Patent examination system, Patents, Right to Health, Sec 3 (d), TRIPS, WTO. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s